Guest guest Posted April 15, 2010 Report Share Posted April 15, 2010 PI is a well respected organisation but I find this statement disturbing in the decision to only present one half of the arguments and then use language to make it all sound reasonable. ie - " at least start before 500 " should be " start before " " careful review " should just be " review " . " Some evidence shows " means that " some evidence doesn't " " may " decrease etc means we don't know. PIs history has been to give people the information they need to make their own decisions, and they are now giving out opinion rather than evidence and worse than this, obscuring other information. At some point in the future, the evidence may be sufficiently strong to recommend treatment above CD4 500 for everyone ready for treatment. The fact is that it isn't there now. This is why the START trial is running - to get real evidence from randomisd study, that will also infomra people of the risks, including side effects and resistance. Yes, we need wider testing and earlier treatment - not the average CD4 count at less that 200 in most countries. The jump to put everyone on treatment at any CD4 count does not follow. Some experts may say yes, some say no, some say we need to get the evidence. Simon <snip> http://www.projectinform.org/info/when/index.shtml * Based upon a careful review of currently available data, Project Inform believes that all HIV-positive people who are ready to begin treatment should start at least before their CD4 counts fall below 500. * Some evidence shows that starting treatment above 500 CD4s - or during acute infection to lower the chance of a low nadir CD4 - may decrease damage to the immune system, promote better longer-term health outcomes, and extend a person's life. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.